Optimizing mesenchymal stem cell extracellular vesicles for chronic wound healing: Bioengineering, standardization, and safety

IF 3.4 3区环境科学与生态学 Q3 CELL & TISSUE ENGINEERING

Regenerative Therapy Pub Date : 2024-06-01 DOI:10.1016/j.reth.2024.06.001

Yusuke Shimizu , Edward Hosea Ntege , Yoshikazu Inoue , Naoki Matsuura , Hiroshi Sunami , Yoshihiro Sowa

{"title":"Optimizing mesenchymal stem cell extracellular vesicles for chronic wound healing: Bioengineering, standardization, and safety","authors":"Yusuke Shimizu , Edward Hosea Ntege , Yoshikazu Inoue , Naoki Matsuura , Hiroshi Sunami , Yoshihiro Sowa","doi":"10.1016/j.reth.2024.06.001","DOIUrl":null,"url":null,"abstract":"<div><p>Chronic wounds represent a significant global burden, afflicting millions with debilitating complications. Despite standard care, impaired healing persists due to factors like persistent inflammation and impaired tissue regeneration. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) offer an innovative regenerative medicine approach, delivering stem cell-derived therapeutic cargo in engineered nanoscale delivery systems. This review examines pioneering bioengineering strategies to engineer MSC-EVs into precision nanotherapeutics for chronic wounds. Emerging technologies like CRISPR gene editing, microfluidic manufacturing, and biomimetic delivery systems are highlighted for their potential to enhance MSC-EV targeting, optimize therapeutic cargo enrichment, and ensure consistent clinical-grade production. However, key hurdles remain, including batch variability, rigorous safety assessment for potential tumorigenicity, immunogenicity, and biodistribution profiling. Crucially, collaborative frameworks harmonizing regulatory science with bioengineering and patient advocacy hold the key to expediting global clinical translation. By overcoming these challenges, engineered MSC-EVs could catalyze a new era of off-the-shelf regenerative therapies, restoring hope and healing for millions afflicted by non-healing wounds.</p></div>","PeriodicalId":20895,"journal":{"name":"Regenerative Therapy","volume":"26 ","pages":"Pages 260-274"},"PeriodicalIF":3.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352320424001081/pdfft?md5=b57ef0386d9c123d53065ac34dd7abca&pid=1-s2.0-S2352320424001081-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative Therapy","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352320424001081","RegionNum":3,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Chronic wounds represent a significant global burden, afflicting millions with debilitating complications. Despite standard care, impaired healing persists due to factors like persistent inflammation and impaired tissue regeneration. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) offer an innovative regenerative medicine approach, delivering stem cell-derived therapeutic cargo in engineered nanoscale delivery systems. This review examines pioneering bioengineering strategies to engineer MSC-EVs into precision nanotherapeutics for chronic wounds. Emerging technologies like CRISPR gene editing, microfluidic manufacturing, and biomimetic delivery systems are highlighted for their potential to enhance MSC-EV targeting, optimize therapeutic cargo enrichment, and ensure consistent clinical-grade production. However, key hurdles remain, including batch variability, rigorous safety assessment for potential tumorigenicity, immunogenicity, and biodistribution profiling. Crucially, collaborative frameworks harmonizing regulatory science with bioengineering and patient advocacy hold the key to expediting global clinical translation. By overcoming these challenges, engineered MSC-EVs could catalyze a new era of off-the-shelf regenerative therapies, restoring hope and healing for millions afflicted by non-healing wounds.

查看原文本刊更多论文

优化用于慢性伤口愈合的间充质干细胞细胞外囊泡：生物工程、标准化和安全性

慢性伤口是全球的沉重负担，数百万人深受其害，并出现使人衰弱的并发症。尽管采取了标准护理措施，但由于持续炎症和组织再生能力受损等因素，伤口愈合受损的情况依然存在。间充质干细胞（MSC）衍生的细胞外囊泡（EVs）提供了一种创新的再生医学方法，在工程纳米级输送系统中输送干细胞衍生的治疗货物。这篇综述探讨了将间充质干细胞-细胞外小泡设计成治疗慢性伤口的精准纳米疗法的开创性生物工程策略。文章重点介绍了 CRISPR 基因编辑、微流体制造和仿生递送系统等新兴技术，这些技术具有增强间充质干细胞-EV 靶向性、优化治疗载体富集和确保临床级生产一致性的潜力。然而，关键的障碍依然存在，包括批次变异性、针对潜在致瘤性的严格安全性评估、免疫原性和生物分布分析。至关重要的是，协调监管科学、生物工程和患者权益的合作框架是加快全球临床转化的关键。通过克服这些挑战，工程间充质干细胞-EV 可催生现成再生疗法的新时代，为数百万无法愈合的伤口患者重新带来希望和痊愈。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative Therapy Engineering-Biomedical Engineering

CiteScore

6.00

自引率

2.30%

发文量

106

审稿时长

49 days

期刊介绍： Regenerative Therapy is the official peer-reviewed online journal of the Japanese Society for Regenerative Medicine. Regenerative Therapy is a multidisciplinary journal that publishes original articles and reviews of basic research, clinical translation, industrial development, and regulatory issues focusing on stem cell biology, tissue engineering, and regenerative medicine.